Interstitial lung diseases (ILDs) are inflammatory diseases characterized by slow and progressive destruction of alveolar-capillary functional units, often leading to respiratory failure and death. A first stage of alveolitis and a following stage of fibrosis provoke an anatomical distortion of the peripheral airways and the interstitium, and for their smoldering evolution and non-specificity of symptoms ILDs may remain undiagnosed and untreated for a long time. In this review we exploited the immunopathogenetic aspects and the therapeutical approaches to this frequently unrecognized and severe disease.
Interstitial lung diseases (ILDs) are inflammatory diseases characterized by slow and progressive destruction of alveolar-capillary functional units, often leading to respiratory failure and death. A first stage of alveolitis and a following stage of fibrosis provoke an anatomical distortion of the peripheral airways and the interstitium, and for their smoldering evolution and non-specificity of symptoms ILDs may remain undiagnosed and untreated for a long time. In this review we exploited the immunopathogenetic aspects and the therapeutical approaches to this frequently unrecognized and severe disease.
Definition
Interstitial lung diseases (lLDs) are inflammatory diseases characterized by alveolar and lung interstitium alterations, which cause progressive scarring of lung tissue followed by a change in peripheral airways and lung blood vessels, often evolving into respiratory failure. The incidence in the general population is about 80 cases out of 100,000 inhabitants, for men, and 70 cases out of 100,000 inhabitants, for women.
Anatomy
The damage to lung parenchyma is caused by activated inflammatory cells accumulated in the alveolar structures. The low respiratory tract is made up of alveoli (cluster emanations of ending bronchioles) and vascular network (arterioles, capillaries and lung venules) ( Fig. la) . Alveolar walls are covered by a single layer of epithelial cells (95% of type I, flat and covering, and 5% of type II, globose and producing surfactant) laying on the basal membrane continuing in the alveolar interstitium, which contains fibroblasts and connective matrix. Capillaries pass through the alveolar interstitium in eccentric position and in the point of confluence of the alveoli, where interstitium extends, there are lymphatic vessels which contribute towards the continuous drainage of liquids and solutes accumulating in the interstitium
/mmunopathogenesis
The essential evolutive phases of ILD can be represented in three main aspects. The initial alterations mostly evolve in an alveolitic phase. This is probably the only partly reversible process stage, provided that the exposition to the damaging aetiological agent stops. This phase is characterized by an abundant protein-rich alveolar exudate, degenerative changes of the alveolar epithelium and capillary endothelium, fibrinoid necrosis, jaline membranes and accumulation of cellular elements (monocytes, lymphocytes, neutrophils, eosinophils) in different proportion and typology according to the disease aetiology and seriousness. The heterogeneity of the inflammatory cells in the interstitium and alveolar space during the alveolitic phase leads to distinguish several types of alveolitis according to the predominant cellular component: lymphocytic alveolitis (which is typical of bacterial and viral interstitial pneumonia and extrinsic allergic alveolitis), plasmacytic (in Pneumocystis and rickettsial lung diseases), eosinophilic (eosinophil, parasitic, iatrogenic lung diseases and Churg-Strauss syndrome), neutrophilic (Hamman-Rich idiopathic fibrosis), histiocyte-macrophagic (pneumoconiosis, idiopathic lung haemosiderosis and Goodpasture's syndrome). After this initial alveolitic phase, there is a reactive and/or reparative phase, during which it is possible to see the development of the typical granulomas made up of a cellular population gathering and organizing to limit the process around necrotic focuses, immune complexes, organic material (fungi, parasites) or inorganic material (crystals, minerals). Not all the alveolar types evolve with the development of the typical granulomas. A common feature is the proliferation of pneumocytes of II type and bronchiolar cells which tend to replace the degenerated epithelial cells of I type. It is possible to see a proliferation of fibroblast elements around the initial elementary lesions and the formation of collagen tissue. The third phase is represented by diffuse fibrosis with disorder of the normal architecture of alveolar septums and walls, presence of excess collagen fibers in the interstistium, damage to alveolar cells and capillaries. Airspaces have irregular areas and fibrin deposition, alveolar walls look thickened and infiltrated by inflammatory cellular elements and fibrotic changes often occur also in capillaries. This end stage lung, towards which most interstitial diseases more or less precociously evolve, is known as honeycomb lung and besides the fibrotic subversion of lung structure, there is an interfibrotic emphysematous distension of the whole lung (1-4). Inflammation is often in the wall of small air ducts and lung blood vessels. Among the inflammatory cells, neutrophils are the most damaging ones because of their highly reactive oxygen metabolites and their proteases which can damage interstitial collagen and basal membranes. Eosinophils can damage lung tissue, but they are much less powerful than neutrophils. The activated alveolare macrophages release oxidants which are toxic for lung parenchymal cells and mediate fibroblast accumulation in the alveolar interstitium, releasing an excessive quantity of platelet derived growth factor (PDGF, the beta chain of which is codified by c-sis proto-oncogene), alveolar macrophage derived growth factor (AMDGF, a type of insulin like growth factor 1) and fibronectine (a glycoprotein which attracts fibroblasts, attaches them to the extracellular matrix and incites them to proliferate). Transforming growth factor (TGF)-P is now considered a key molecule in the pathogenesis of tissue fibrosis in fibrotic disease (5) (6) . One important effect ofTGF-p is the remarkable stimulation ofthe production ofvarious collagens and other extracellular matrix proteins by mesenchymal cells. TGF-p decreases the synthesis of collagendegrading metalloproteinases and stimulates the production of tissue inhibitors ofmetalloproteinases. It sensitizes fibroblasts to their own effects and maintains them in a persistently activated state by an autocrine mechanism that causes further production of TGF-p (7) (8) . Various cells including fibroblasts and macrophages produce TGF-p, and most cells in the body have receptors for TGF-p. TGF-p binds to a serine threonine transmembrane kinase known as the TGF-p type II receptor (TGF-PRII), which is intrinsically active. The signalling events that follow are complex and involve several intracellular molecules and pathways (9) (10) . The complex of TGF-p and TGFpRII recruits another receptor, TGF-P type I receptor, to form a larger complex. Signaling from the TGF-p receptor complex to the nucleus then occurs through proteins called Smads, which mediate the activity of TGF-p. In the nucleus, the SMAD complex binds to specific DNA binding sites in promoter regions of target genes with the help of intranuclear transcriptional partners. This binding modulates the transcriptional activity of genes that encode extracellular matrix proteins, such as the u 1 and U z chains of type I collagen, or of extracellular matrix regulatory proteins, such as connective tissue growth factor (11-12).
CLASSIFICATION
There are many principles to be used for a classification. A classification differentiates interstitial lung diseases into three subgroups: I) idiopathic primitive types -when it is not possible to identify any factor causing the disease; 2) primitive types -caused by known aetiological factors; 3) secondary types -which develop in the presence of other morbid processes. A clinical distinction providing for acute and chronic types can be connected with this first classification and the first ones may represent the onset of chronic types and may arrive at resolution if they are still in the alveolar stage. A classification based on pathological criteria provides for 7 types ofinterstitial pneumonia: 1) usual interstitial pneumonia (VIP) is the most frequent interstitial pneumonia. With regard to the aetiological aspect, it starts with an alveolar damage, edema and the formation of jaline membranes, followed by cellular infiltration of the interstitium and increase of fibroblasts. If the damaging aggression continues, fibroblast proliferation and the deposition of collagen fibers become more marked causing a great change of lung structure, up to the honeycomb lung. The presence of non-uniform and non-homogeneously distributed interstitial changes, with the alternation of areas of interstitial fibrosis, inflammation and serious distortion of tissue structure, is an important element for VIP diagnosis. The prevailing component of fibrosis consists of eosinophil collagen with few inflammatory or stromal cells associated. The deposited collagen thickens the alveolar septums and creates cicatricial areas with dilated air spaces, covered by bronchiolar epithelium or hyperplastic alveolar pneumocytes, divided by thick walls containing collagen fibers and a varying quantity of chronic inflammatory infiltrate. The enlarged air spaces may be empty but they often contain thick mucus mixed with histiocytes, neutrophils and other inflammatory cells. Although most fibrosis areas are made up ofrelatively acellular collagen, it is possible to identify small fibroblast and myofibroblast actively proliferating aggregates, called "fibroblast foci". These aggregates are characterized by fusiform cells, which are plunged in a clear myxoid matrix and oriented parallel to alveolar septa with their main axis. Electronic microscopy has highlighted that these foci represent the organization of areas of previous acute lung lesion and are characterized by active collagen synthesis. The inflammatory component is usually slight and mostly made up of small lymphocytes, rare plasma cells, few neutrophils and eosinophils. The intraalveolar accumulation of macrophages is a common but not specific VIP's report and it is not connected with the disease stage ( Fig. 1 b) ; 2) bronchiolitis obliterans with classic interstitial pneumonia (BIP), currently called bronchiolitis obliterans with organizing pneumonia (BOOP), is different from the previous one because of the presence of a bronchiolitis and mononuclear cells with fats in the interstitium and alveoli, which is the expression of a lipoic pneumonia; 3) desquamative interstitial pneumonia (DIP) characterized by mononuclear cells, above all macrophages, mostly in alveoli than in the interstitium. These cells have abundant cytoplasm, which often contains a dark yellow, finely granular pigment, deriving from the phagolysosomial complex. Most cells are mononuclear but huge multinucleated cells can also be observed. These cells were considered epithelial cells exfoliated or "scaled off" from alveolar septums, so that the definition desquamative is not correct. A minimum or moderate widening of alveolar septa often occurs together with the changes of air spaces and it is mostly characterized by collagen deposition with poor inflammatory infiltrate, while many hyperplastic alveolar epithelial cells are evident. The macrophage accumulation is usually marked in peribronchiolar air spaces. However, if it is limited to these areas with the exception of more distal air spaces, the process is called respiratory bronchiolitis interstitial lung disease (RB-ILD). It seems likely that these two kinds of changes represent different results of the same pathological process and the definition RB-ILD should replace DIP because it is anatomically more correct ( Fig. 1 c) ; 4) acute interstitial pneumonia (AlP), characterized by active interstitial fibrosis, with proliferating fibroblast and myofibroblast and a minimum collagen deposition. Changes are temporarily uniform and seem to be relatively acute and fibroblast proliferation occurs in a myoxomatous stroma, with the thickening of alveolar septa, epithelial necrosis, alveolar collapse, proteoglycan deposition, jaline membranes in alveolar spaces ( Fig. 1 d) ; 5) non-specific interstitial pneumonia (NSIP), characterized by different degrees of inflammation and fibrosis in the alveolar spaces, in the absence of specific changes indicating a VIP, DIP or AlP diagnosis. It is usual to highlight changes characterized by tissue infiltration of lymphocytes and plasma cells, mostly in peribronchiolar interstitium, together with a marked hyperplasia of alveolar pneumocytes ( Fig. I.e ); 6) lymphoid interstitial pneumonia (LIP), characterized by lymphoid and plasma cellular infiltration of alveolar septa and peribronchiolar and periarteriolar interstitium; 7) giant cell interstitial pneumonia (GIP) is less common than the others and has a lymphocytic and plasmacytic infiltrate with giant cells in alveoli in a great phagocytic activity and they can be, in fact, defined as cannibal. These types, more than autonomous entities, are considered different evolutive phases of an interstitial reaction to equal stimuli or expressions of a lung change as a reaction to damaging agents of different kinds (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Another classification links interstitial lung diseases with more or less homogeneous aetiological factors, marking two main groups: a) interstitial lung diseases of known aetiology (infective agents, organic dusts, inorganic dusts, chemical dusts, gases, fumes, exhalations, aerosols, poisons, ionizing radiations, medicines); b) interstitial lung diseases of unknown aetiology (familiar and sporadic idiopathic lung fibrosis, collagen-vascular diseases, sarcoidosis, histiocytosis X, Goodpasture syndrome, eosinophilic pneumonia, lymphangioleiomyomatosis, hereditary diseases, infiltrative lymphocytic diseases, lung vasculitis, idiopathic lung haemosiderosis, alveolar proteinosis, lower airways diseases, Weber-Christian disease, hypereosinophilic syndromes, lung veinocclusive disease, lung carcinomatous lymphangitis, haemodynamic changes, chronic kidney failure, gastro-esophageal reflux with chronic aspiration, bowel diseases, liver diseases) and a newer one considers: I) idiopathic interstitial pneumonias 2) environmental and occupational diseases 3) multisystem diseases 4) rare lung diseases.
CLINICAL ASPECTS ILD first clinical manifestations are a reduced exercise tolerance and easy fatigue, the appearance of dyspnoea, caused by exercise at first and then present even at rest, non-productive cough, pleuritic chest pain. Systemic symptoms, such as fever, a general malaise, arthralgia and loss of weight may occur. In the first phases of the disease, the chest pain is sporadic, but when lung hypertension occurs, a retrosternal discomfort may be felt.
Physical examination
Chest hypoexpansibility, inspiratory and expiratory crepitating rales (velcro-like), sometimes rough rales, wheeze and rhoncus occur. When lung hypertension starts, it is possible to notice an intensification of lung component of the second tone and an epigastric pulsation. Other reports are digital hippocratism and cyanosis. The presence of collagen-vascular diseases may be suggested by synovitis, telangiectasias, sclerodactyly and malar rash. Sarcoidosis may involve extrapulmonary organs and is suspected if uveitis, nodous erythema or skin lesions, which are typical of skin sarcoidosis (lupus pernio), occur. The cardiovascular examination may reveal mitral stenosis, chronic lung venous congestion or left ventricle failure.
Laboratory tests
There is no diagnostic haematochemical test for ILDs, but a screening for haematologic, liver, kidney, muscle, collagen disease and HIV infection may be useful. There could be a slight anaemia, erythosedimentation rate and reactive protein C may be elevated. The occasional presence of rheumatoid factor, cryoglobulins and antinuclear antibodies do not necessarily indicate the presence of a collagen disease. In case of sarcoidosis, cytopenia may occur ifbone marrow is involved and we may find hypercalcemia and alteration of liver function; angiotensin-converting enzyme (ACE) is usually elevated, but this is also found in miliary tuberculosis, berylliosis, asbestosis and silicosis. Cytopenia may also occur in collagen-vascular and neoplastic diseases. Peripheral eosinophilia may suggest chronic eosinophilic pneumonia. Hypersensitivity pneumonia is almost always connected with serum antibodies against the casual agent, but they may suggest an antigen exposure determining an immunologic response and do not necessarily show that ILD is connected with an 
b) UIP slight enlargement showing the typical variation ofhistological situation from one area to the other. It is possible to see interstitial fibrosis with a dense collagen deposition and scattered areas containing normal alveolar septa and enlarged air spaces full of mucus (x 48). c) DIP slight enlargement showing alveolar spaces full of macrophages with a moderate thickening of alveolar septa. Changes are evenly distributed (x 120). d) AlP photomicrography showing the typical uniform thickening ofalveolar septa by mononuclear cells (x 120) -e) NSIP photomicrography showing a ranging and uniform thickening ofalveolar septa (x 120)
extrinsic allergic alveolitis.
X-ray tests
In the initial phases chest X-ray may show a ground glass type and then a nodular, reticular or reticular-nodular type, above all in the peripheral parenchyma and lung bases. The decreased parenchymal distensibility may determine traction bronchiectasis looking like thickened and dilated airways and, with the evolution of the disease, cystic areas may appear. High resolution computed tomography (HRCT) underlines a decrease in lung volume, peripheral reticular anomalies with a not uniform distribution, linear or reticular intralobular interstitial opacities, an irregular thickening of the septa, different types of honeycomb lung, above all in the subpleural areas, and traction bronchiectasis.
Breathingfunctionality tests
There is a harmonic reduction of all lung volumes (total lung capacity, residual volume, residual functional capacity) with a regular or increased Tiffeneau index (forced expiratory volume in I second/forced vital capacity, FEVIIFVC) and reduced diffusion capacity. Haemogasanalysis reveals a slight hypoxaemia (at rest caused by a non-homogeneneous distribution of lung ventilation and perfusion, whereas, during exercise, it is caused by a rapid blood flow through pulmonary or extrapulmonary capillaries or by a patent foramen ovale) and normocapnia or hypocapnia. Assessment offunctional capacity may be obtained by the Six-Minute Walk Test (6MWT) which is a test that requires a 100-ft hallway but no exercise equipment or advanced training for technicians. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes (the 6MWD). It evaluates the global and integrated responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism.
Scintigraphy
Conventional ventilation and perfusion scintigraphy shows many distribution faults and lack of homogeneity. Gallium-66 scintigraphy reveals an active captation of radiotracer, above all in activated alveolar macrophage types. 99mTc-DTPA aerosol, a hydrophilic agent, is eliminated more quickly when capillary permeability is increased and may provide a lung inflammation index.
Bronchoscopy
Optical fiber bronchoscopy may be connected with transbronchial biopsy and bronchoalveolar lavage (BAL), that may evaluate the type and state of inflammatory cell activation and enzymes liberated. The alveolar lavage fluid of a normal subject usually contains 84-99% of macrophages, 1-14% of lymphocytes, 0-1% of neutrophils.
Biopsy
ILD diagnosis depends on the histological examination of bioptic samples. Tissue samples taken through fibrobronchoscopy are usually too small to allow an appropriate histological assessment, therefore a biopsy through thoracoscopy or thoracotomy is necessary (25) (26) (27) .
Follow-up ofILD
Follow-up ofthe course ofdisease and treatment outcome includes lung X-ray and respiratory function assessment (plus ACE determination at 1-or 2-month intervals in case of sarcoidosis). The criteria of severe alveolitis include lymphocyte predominance in bronchoalveolar lavage (cytology) and immunologic parameters, i.e. high percentage of the T-lymphocytes (>28%) and a CD4:CD8 ratio exceeding 3.5. HRCT is of great value in detecting the interstitial lesions of the initial stages of disease and provides an excellent tool for long-term follow-up.
Prognosis
ILDs are a heterogeneous group of pathological conditions, the natural history of which is influenced by the specific diagnosis and the extent and severity of lung involvement, and prognosis depends on the cause and on the possibility of treatment. Prognosis is worse with advanced age, poor pulmonary function at presentation (forced vital capacity [FVC] < 55% of predicted or diffusion lung· capacity for carbon monoxide [DLCO] < 35% of predicted), and severe dyspnea. IPF and connective tissue diseaseassociated ILD have the worse prognosis, as patients have moderate to advanced clinical disease at the time of diagnosis, deteriorate despite treatment and have a nine-year survival rate ofless than 30% (mean survival of3-6 years). A better prognosis is predicted by normal Pa0 2 at presentation and fewer fibroblastic foci on biopsy. Causes of acute deterioration include infections, pulmonary embolism, pneumothorax and heart failure, but acute exacerbations without an identifiable cause are common and have a high morbidity. Lung cancer occurs more frequently in patients with IPF, but the causes of death are usually respiratory failure, respiratory infection, heart failure with ischemia and arrhythmia. Because of the poor prognosis of IPF, discussions with the patient and family regarding advanced care planning and endof-life management are important at the early stages of diagnosis and management.
THERAPY
Therapeutic choice and possibility are connected with the kind of interstitial lung disease which is diagnosed. The IPF treatment is based on the idea that the accumulation of inflammatory and immunocompetent cells causes lung parenchyma change and fibrosis.Although this idea ofpathogenetic process theoretically suggests many therapeutic options, the real available stategy is based on the use of anti-inflammatory drugs and lung transplantation. In fact, to date, no pharmacological therapy has been able to eliminate the inflammatory component and reduce the fibrosis process. Therapeutic options include corticosteroids, immunosuppressants and antifibrotic agents, to be used alone or together (28) .
Corticosteroids
Although they are largely used, no perspective, randomized, placebo controlled research has shown corticosteroid effectiveness in IPF treatment. A complete and lasting remission has been achieved in a few cases and, even in patients showing an initial good reaction, a relapse or disease progression occurred, therefore it is necessary to continue with therapy for a long period. It is necessary to start with a high dosage by mouth (40-100 mg/day of prednisone or prednisolone for 2-4 months, with a following gradual reduction); high dosage intravenous medication (1-2 gr at 7-14 day intervals) has not been more effective than oral therapy. In case of response to therapy, the improvement becomes evident within 3 months and it is estimated by objective clinical parameters (dyspnoea score) and instrumental parameters (spirodiffusometric tests, X-ray tests). Maintenance steroidal therapy has to be continued, if not indefinitely, at leat for 1-2 years and a sufficient dosage could be 15-20 mg on an alternate-day regimen. In case of relapse or worsening, it is necessary to increase the dosage or add an immunosuppressant.
Cytotoxic agents
Immunosuppressants (azathioprine, cyclophosphamide, cyclosporin A, methotrexate) are used for patients who do not respond to steroidal therapy, show serious side effects or have high complication risk (diabetes mellitus, high blood pressure, serious osteoporosis, peptic ulcer). The benefits of these medicines are not evident and their potential lung and systemic toxicity has to be considered.
Cyclophosphamide, a cytotoxic nitrogen mustardtype alkylating agent, does not appear to improve survival in IPF and a marginal improvement in forced vital capacity was reported in only one investigation. In patients who do not respond to the steroidal therapy, the use of high dosage intravenous cyclophosphamide has been tried (500-1800 mg every 2-4 weeks).
Azathioprine is an antimetabolite that inhibits purine incorporation into nucleic acids, suppresses cell-mediatedcytotoxicityanddelayedhypersensivity responses via inhibition of T lymphocytes, but is generally considered to be less potent and slower in onset than cyclophosphamide. The treatment with azathioprine or cyclophosphamide is often recommended for patients with IPF due their poor prognosis.
Cyclosporine blocks calcineurin in T-cells and thereby prevents the elaboration of cytokines necessary for T-cell maturation and proliferation. In uncontrolled trials, cyclosporine was reported to decrease steroid dosage and to initially improve symptoms and pulmunary function test. Cyclosporine does not appear to improve pulmunary manifestations ofsarcoidosis, but it has been reported to be beneficial for individualized cases of ILD associated with rheumatoid arthritis, polymyositis/ dermatopolyrnyositis and other connective tissue disorders.
Hydroxycloroquine is an anti-malarial agent with immunosoppressive properties that are mediated via unknown mechanisms. It has been used to treat rheumatologic disease such as rheumatoid arthritis and systemic lupus erythematosus, and hydroxycloroquine has been the drug of choice as a steroid-sparing agent for the treatment of paediatric interstitial lung disease. It has been used as a steroidsparing agent for the treatment of sarcoidosis, but its efficacy for the treatment of pulmonary sarcoidosis is not clear.
N-acetylcysteine and other anti-oxidant agents
An oxidant-antioxidant imbalance may contribute to the disease process in idiopathic pulmonary fibrosis, and a protective role can be played by molecules with antioxidant capacity (glutatyon, N-acetylcysteine, taurine, niacin) as the lung tissue damage is also mediated by oxygen free radicals. The IFIGENIA (Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual) trial has evidenced that N-Acetylcysteine, a precursor of the major antioxidant glutathione, given at a daily dose of 1800 mg, restores depleted pulmonary glutathione levels and results in a statistically significant improvement in lung function in patients with fibrosing alveolitis after 12 weeks of treatment.
Agents influencing collagen synthesis andfibrosis
These agents can inhibit fibrogenesis and interfere with matrix synthesis, fibroblast proliferation and cellular profibrotic stimulation, but to date their benefit has not been confirmed by randomized and controlled clinical trials. Colchicine inhibits the formation of collagen, modulates in vitro and in vivo extracellular environment and suppresses macrophage growth factor and fibronectine production by alveolar macrophages which have been taken from subjects suffering from IPF and cultivated in vitro. An oral dosage of 0.6 mg once a day or bis in die can be used as the first line therapy or in patients who are refractory to steroidal therapy, to be used alone or together with immunosuppressants. Other antifibrotic agents, which are being tested for lung fibrosis treatment, are pyrphenydone and alphugynone (inhibiting collagen synthesis), relaxin (causing procollagenase), suramine (inhibiting profibrotic cytokines), endotheline-l and angiotensin-II opponents (vessel active peptides with a mitogen action on fibroblasts). Among immunoregulators, the interferon y can reduce transforming growth factor~1, which is greatly involved in fibroblast proliferation and collagen deposition. A randomized, placebo-controlled trial showed that interferon did not attenuate disease progression. However, subgroup analysis from Raghu's trial, as well as a more recent study comparing colchicine and interferon for IPF, suggested that a long-term survival benefit may exist for those with mild to moderate disease. Other molecules under study are interleukin 4, interleukin 7, interleukin 13, and prostaglandin PGE2, and another possible strategy is represented by immunotherapy.
Lung transplant
Lung transplant may be a potential alternative in the absence of a valid therapy in patients who are under 55 years of age and have no contraindication. Many patients are improved by the transplant of one lung which allows a better use of the poor resources. Unfortunately, many patients have co-morbidities or other factors (e.g. advanced age) that prevent them from being considered for lung transplant, and the 5-year survival rate, while increased somewhat over the last two decades, still hovers at approximately 50% of patients transplanted for ILD.
New biologic agents
The excessive production of pro-inflammatory cytokines such as IL-l, TNF, and IL-6, which is a fundamental pathogenetic mechanism in rheumatologic diseases, and newer agents that antagonize these cytokines or their receptors are being employed in the treatment ofcollagen vascular disorders and may eventually prove useful in treating various forms of ILD that are not associated with any systemic rheumatologic disorder. Many of these agents are antibodies directed against cytokines (e.g. infliximab, etanercept, rituximab, abatacept, anakinra) or cytokine receptor antagonists and have been evaluated in large, prospective, randomized, placebo-controlled clinical trials .
